Outcomes, Trends, and Predictors of Gastrointestinal Bleeding in Patients Undergoing Transcatheter Aortic Valve Implantation (from the National Inpatient Sample)

Zahid, Salman; Khan, Muhammad Zia; Bapaye, Jay; Altamimi, Tamer Salhab; Elkhapery, Ahmed; Thakkar, Samarthkumar; Nepal, Mahesh Raj; Rai, Devesh; Ullah, Waqas; Patel, Harsh; Sattar, Yasar; Rahman, Asad Ur; Balla, Sudarshan

doi:10.1016/j.amjcard.2022.01.022

Cited by 7 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As noted, bleeding complications have steadily declined in TAVI patients, but remain a significant factor in post-TAVI morbidity and mortality 41. Data from the STS/transcatheter valve therapy (TVT) registry describe a large cohort of over 275 000 patients undergoing TAVI from 2011 to 2019, in which in-hospital life-threatening bleeding declined from 6.3% in early TAVI experience to 2.3% in 2019 among high-risk patients 42.…”

Section: Structural Complicationsmentioning

confidence: 99%

“…Prostate and active surveillance cancers (eg, chronic lymphocytic leukaemia) may have the lowest all-cause 1-year mortality among patients with cancer, likely reflective of a more indolent disease state whereas leukaemia and lung cancer have worse long-term outcomes 33 35. Gastrointestinal bleeding following TAVI was highest in patients with active colorectal (OR 7.8; 95% CI 5.33 to 11.70), lung (OR 2.80; 95% CI 1.77 to 4.41) and metastatic cancer (OR 2.16; 95% CI 1.48 to 3.16) with associated increased mortality among all-comers with bleeding during index hospitalisation 41…”

Section: Tavi Outcomes In Cancermentioning

confidence: 99%

See 1 more Smart Citation

Transcatheter aortic valve intervention in patients with cancer

Leedy

Elison

Farias

et al. 2023

Heart

View full text Add to dashboard Cite

The prevalence of concurrent cancer and severe aortic stenosis (AS) is increasing due to an ageing population. In addition to shared traditional risk factors for AS and cancer, patients with cancer may be at increased risk for AS due to off-target effects of cancer-related therapy, such as mediastinal radiation therapy (XRT), as well as shared non-traditional pathophysiological mechanisms. Compared with surgical aortic valve replacement, major adverse events are generally lower in patients with cancer undergoing transcatheter aortic valve intervention (TAVI), especially in those with history of mediastinal XRT. Similar procedural and short-to-intermediate TAVI outcomes have been observed in patients with cancer as compared with no cancer, whereas long-term outcomes are dependent on cancer survival. Considerable heterogeneity exists between cancer subtypes and stage, with worse outcomes observed in those with active and advanced-stage disease as well as specific cancer subtypes. Procedural management in patients with cancer poses unique challenges and thus requires periprocedural expertise and close collaboration with the referring oncology team. The decision to ultimately pursue TAVI involves a multidisciplinary and holistic approach in assessing the appropriateness of intervention. Further clinical trial and registry studies are needed to better appreciate outcomes in this population.

show abstract

Section: Structural Complicationsmentioning

confidence: 99%

Section: Tavi Outcomes In Cancermentioning

confidence: 99%